Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
Pharmacology, Toxicology and Pharmaceutical Science
5
10%
Biochemistry, Genetics and Molecular Biology
4
8%
Agricultural and Biological Sciences
4
8%
Nursing and Health Professions
3
6%
Other
1
2%
Unknown
20
39%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 May 2022.
All research outputs
#7,591,076
of 34,410,315 outputs
Outputs from Cancer (0008543X)
#6,502
of 18,989 outputs
Outputs of similar age
#38,694
of 166,461 outputs
Outputs of similar age from Cancer (0008543X)
#38
of 134 outputs
Altmetric has tracked 34,410,315 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 18,989 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.2. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,461 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 134 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
